Hopital Prive D Antony — Clinical Trial Site

49 Registered trials

21 Currently recruiting

Organisation

Hopital Prive D Antony

Location

Antony, France

Identifier

ORG-100045320

Address

1 Rue Velpeau, 92160, France

Departments

#40245: Service de dermatologie
#5001: Dermatology
#5002, Dermatologie
#5004:Dermatology
1503: Dermatologie
9204; Maladies auto-immunes et de dermatologie
Département d’Hématologie
Department of Dermatology
Dermato-vénérologie
Dermatologie Venereologie
Dermatology
Gastroenterology
hematologie
Hepato-Gastro-Entérology
Hôpital Privé d'Antony Service de Dermatologie
N/A
Oncologie médicale
oncology
Pneumologie
Service d’Hématologie
Service de Dermatologie
Service hématologie
Unité de Dermatologie et Immunologie Clinique

Clinical trials at this site (49)

Search interface

A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending

2025-524078-40-00 Chronic Spontaneous Urticaria 5
A study to test how well an oral medication called rilzabrutinib works and how safe it is for adults with immune thrombocytopenia (ITP) who … Recruiting

2025-522070-36-00 immune thrombocytopenia (ITP) 5 2025-12-15
Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting

2025-521293-34-00 Moderate-to-severe hidradenitis suppurativa 4 2025-12-09
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting

2024-511879-16-00 Prurigo Nodularis 5 2024-12-12
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting

2022-502548-12-00 marginal zone lymphoma 5 2023-09-28
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
Brivekimig for the treatment of moderate to severe hidradenitis suppurativa Recruiting

2025-522333-61-00 Hidradenitis suppurativa 4 2026-01-23
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum Recruiting

2024-514306-31-00 Pyoderma gangrenosum 5 2025-02-13
A proof-of-concept study to learn whether linvoseltamab can eliminate abnormal plasma cells that may lead to multiple myeloma in adult patie… Recruiting

2023-505242-25-00 High-Risk Monoclonal Gammopathy of Undetermined Signifi 4 2024-11-05
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
68Ga-FAPI-46 PET/CT for predicting histological response in triple-negative breast cancer Recruiting

2023-507860-37-00 Breast cancer 9 2024-10-14
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge… Recruiting

2024-511070-68-01 Ampullary adenocarcinoma 5 2024-09-24
A Window of Opportunity Trial To Learn If Linvoseltamab Is Safe And Well Tolerated, And How Well It Works In adult Participants With Recentl… Recruiting

2022-500800-24-00 Multiple Myeloma 4 2024-09-19
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul… Recruiting

2023-504863-17-00 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic 5 2024-02-21
Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting

2023-503661-28-00 Hidradenitis Suppurativa 5 2023-10-26
A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut… Recruiting

2023-505634-94-00 Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneo 10 2023-02-02
PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first… Ended

2024-518553-41-00 colon cancer and rectal with liver metastasis 5 2024-11-08
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30